BEIJING, Jan 8 (Reuters) – Talks to incorporate Pfizer’s Paxlovid in its newest record of medication for primary authorities medical health insurance haven’t been profitable, the China Well being Safety Administration stated on Sunday.

The failure of the talks was because of Pfizer’s excessive quoting for Paxlovid. Pfizer didn’t instantly reply to a request for remark.

Reporting: Brenda Goh and Yingzhi Yang Enhancing: Raissa Kasolowsky

Our requirements: Thomson Reuters Trust Principles.